ZD1839 ('Iressa') as an anticancer agent.

Abstract:

:ZD1839 ('Iressa') is an orally active, selective epidermal growth factor receptor-tyrosine kinase inhibitor which blocks signal transduction pathways implicated in the proliferation and survival of cancer cells and other host-dependent processes promoting cancer growth. In preclinical studies, ZD1839 produced reversible growth inhibition and growth delay in a wide range of tumour cell lines and human tumour xenografts. Moreover, this activity was enhanced when ZD1839 was coadministered with cytotoxic agents. Preliminary results from phase I trials in patients with advanced disease and a wide variety of tumour types suggest that ZD1839 has an acceptable tolerability profile and promising clinical efficacy, particularly in non-small cell lung cancer (NSCLC). ZD1839 is currently in phase III clinical development for the treatment of advanced NSCLC. In addition, further trials are ongoing or planned in a number of other tumour types.

journal_name

Drugs

journal_title

Drugs

authors

Baselga J,Averbuch SD

doi

10.2165/00003495-200060001-00004

subject

Has Abstract

pub_date

2000-01-01 00:00:00

pages

33-40; discussion 41-2

eissn

0012-6667

issn

1179-1950

journal_volume

60 Suppl 1

pub_type

杂志文章,评审

相关文献

DRUGS文献大全
  • Abiraterone acetate: in metastatic castration-resistant prostate cancer.

    abstract::Oral abiraterone acetate, in combination with prednisone/prednisolone, is used to treat patients with metastatic castration-resistant prostate cancer (CRPC) who have previously received docetaxel-containing chemotherapy. Abiraterone acetate was developed to specifically inhibit cytochrome P450 (CYP)17A1, which is an e...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.2165/11208080-000000000-00000

    authors: Yang LP

    更新日期:2011-10-22 00:00:00

  • Clostridium difficile-associated disease: changing epidemiology and implications for management.

    abstract::Clostridium difficile-associated disease (CDAD) is increasingly being reported in many regions throughout the world. The reasons for this are unknown, are likely to be multifactorial, and are the subject of several current investigations. In addition to the upsurge in frequency of CDAD, an increased rate of relapse/re...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200767040-00001

    authors: Owens RC

    更新日期:2007-01-01 00:00:00

  • Aspirin-induced asthma: clinical aspects, pathogenesis and management.

    abstract::Aspirin (acetylsalicylic acid)-induced asthma (AIA) consists of the clinical triad of asthma, chronic rhinosinusitis with nasal polyps, and precipitation of asthma and rhinitis attacks in response to aspirin and other NSAIDs. The prevalence of the syndrome in the adult asthmatic populations is approximately 4-10%. Res...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200464210-00004

    authors: Hamad AM,Sutcliffe AM,Knox AJ

    更新日期:2004-01-01 00:00:00

  • Ambulatory blood pressure monitoring.

    abstract::This paper reviews the evidence that, in patients with hypertension, end-organ damage correlates more closely with blood pressure values obtained by ambulatory blood pressure monitoring than with those obtained by conventional sphygmomanometry. However, ambulatory blood pressure monitoring is not suitable for routine ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199200441-00004

    authors: Mancia G,Omboni S,Ravogli A,Frattola A,Villani A

    更新日期:1992-01-01 00:00:00

  • Ondansetron. An update of its therapeutic use in chemotherapy-induced and postoperative nausea and vomiting.

    abstract::Ondansetron is a selective 5-HT3 receptor antagonist which has previously been reported in the Journal to be a promising new agent for use as prophylaxis against nausea and vomiting caused by chemotherapy and radiotherapy. Since the publication of this original review, further studies have been published that show ond...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199345060-00006

    authors: Markham A,Sorkin EM

    更新日期:1993-06-01 00:00:00

  • Systemic glucocorticoid therapy: a review of its metabolic and cardiovascular adverse events.

    abstract::The prevalence of use of long-term systemic glucocorticoid therapy in the general adult population is 1 %. This figure increases to up to 3 % in elderly women. Metabolic (i.e. diabetes mellitus, dyslipidemia, weight gain, lipodystrophy) and cardiovascular (i.e. hypertension, cardiovascular events) adverse events are c...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-014-0282-9

    authors: Fardet L,Fève B

    更新日期:2014-10-01 00:00:00

  • Optimal antagonism of the Renin-Angiotensin-aldosterone system: do we need dual or triple therapy?

    abstract::The cardiovascular and cardiorenal disease continuum comprises the transition from cardiovascular risk factors to endothelial dysfunction and atherosclerosis, to clinical complications such as myocardial infarction (MI) and stroke, to the development of persistent target-organ damage and, ultimately, to chronic conges...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/11537910-000000000-00000

    authors: Werner C,Pöss J,Böhm M

    更新日期:2010-07-09 00:00:00

  • Liposomal drug formulations. Rationale for development and what we can expect for the future.

    abstract::Liposomes are versatile drug carriers which can be used to solve problems of drug solubility, instability and rapid degradation. Both hydrophilic and hydrophobic drugs can be associated with liposomes and special techniques have been developed for the efficient loading of weak acids and weak bases into liposomes. Lipo...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199856050-00001

    authors: Allen TM

    更新日期:1998-11-01 00:00:00

  • Cyclo-oxygenase isoenzymes. How recent findings affect thinking about nonsteroidal anti-inflammatory drugs.

    abstract::The discovery of at least 2 cyclo-oxygenase (COX) isoenzymes, referred to as COX-1 and COX-2, has updated our knowledge of nonsteroidal anti-inflammatory drugs (NSAIDs). This has lead investigators to reconsider what can be awaited from this class of drugs. The 2 COX isoenzymes share structural and enzymatic similarit...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199753040-00003

    authors: Jouzeau JY,Terlain B,Abid A,Nédélec E,Netter P

    更新日期:1997-04-01 00:00:00

  • Tumour necrosis factor in chronic heart failure: a peripheral view on pathogenesis, clinical manifestations and therapeutic implications.

    abstract::The development of chronic heart failure (CHF) includes phenotypic changes in a host of homeostatic systems so that, as the disease advances, CHF may be seen as a multi-system disorder with its origins in the heart but embracing many extra-cardiac manifestations. Immunological abnormalities are recognised in this cont...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200060060-00002

    authors: Bolger AP,Anker SD

    更新日期:2000-12-01 00:00:00

  • Viral respiratory tract infections in transplant patients: epidemiology, recognition and management.

    abstract::Viral respiratory tract infections (RTIs) are common causes of mild illness in immunocompetent children and adults, with occasional significant morbidity or mortality in the very young, very old or infirm. However, recipients of solid organ transplants (SOT) or haematopoietic stem cell transplants (HSCT) are at marked...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200767100-00004

    authors: Lee I,Barton TD

    更新日期:2007-01-01 00:00:00

  • Mammalian cell-derived somatropin : a review of its use in the management of HIV-associated wasting.

    abstract::HIV-associated wasting, characterised by progressive loss of lean body mass and bodyweight, remains a significant problem in the era of highly active antiretroviral therapy (HAART). Loss of body cell mass, a component of lean body mass, is associated with decreased survival. Somatropin (recombinant human growth hormon...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200666030-00014

    authors: Goldsmith DR,Wagstaff AJ

    更新日期:2006-01-01 00:00:00

  • A new strategy for the treatment of inflammatory pain. Prevention or elimination of central sensitization.

    abstract::The optimal treatment of pain requires an understanding of the mechanisms involved. Pain is a sensory end-point that can be generated by a number of dissimilar processes. Consequently, the concept of treating pain as a unitary symptom is obsolete. The mechanisms responsible for specific types of pain need to be unders...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199400475-00003

    authors: Woolf CJ

    更新日期:1994-01-01 00:00:00

  • Are there potential non-lipid-lowering uses of statins?

    abstract::Recent clinical trials have demonstrated beyond doubt that statins are effective in the prevention of acute coronary events. Critical analysis of these studies suggests that the benefits of statin therapy cannot be fully explained on the basis of reductions in plasma cholesterol levels. Accumulating knowledge of the a...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199856040-00001

    authors: Wheeler DC

    更新日期:1998-10-01 00:00:00

  • Lapatinib: a review of its use in the treatment of HER2-overexpressing, trastuzumab-refractory, advanced or metastatic breast cancer.

    abstract::Lapatinib (Tyverb, Tykerb) is an orally active, small molecule, reversible, dual tyrosine kinase inhibitor of human epidermal growth factor receptor type 1 (HER1) and type 2 (HER2). In the EU, lapatinib in combination with capecitabine is indicated for the treatment of women with HER2-overexpressing, advanced or metas...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/11203240-000000000-00000

    authors: Frampton JE

    更新日期:2009-10-22 00:00:00

  • Clinical pharmacology, therapeutic use and potential of COMT inhibitors in Parkinson's disease.

    abstract::When peripheral decarboxylation is blocked by carbidopa or benserazide, the main metabolic pathway of levodopa is O-methylation by catechol-O-methyltransferase (COMT). Entacapone and tolcapone are new potent, selective and reversible nitrocatechol-type COMT inhibitors. Animal studies have demonstrated that entacapone ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200059060-00004

    authors: Kaakkola S

    更新日期:2000-06-01 00:00:00

  • Recent developments in salvage chemotherapy for patients with metastatic soft tissue sarcoma.

    abstract::The number of effective cytotoxic agents for the treatment of patients with metastatic adult soft tissue sarcoma is limited, especially when patients have failed anthracycline- and ifosfamide-based chemotherapy. For the subgroup of patients with inoperable gastrointestinal stromal tumour (GIST), progress has been made...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200565020-00002

    authors: Hartmann JT,Patel S

    更新日期:2005-01-01 00:00:00

  • Porcine-derived lung surfactant. A review of the therapeutic efficacy and clinical tolerability of a natural surfactant preparation (Curosurf) in neonatal respiratory distress syndrome.

    abstract::Porcine-derived lung surfactant (PLS; Curosurf) has shown efficacy in neonatal respiratory distress syndrome. PLS consists of phospholipids, mainly dipalmitoylphosphatidylcholine, the primary surface-active agent of natural lung surfactant, and pulmonary surfactant-associated proteins which facilitate spreading and ad...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199448030-00006

    authors: Wiseman LR,Bryson HM

    更新日期:1994-09-01 00:00:00

  • Does effective management of sleep disorders reduce depressive symptoms and the risk of depression?

    abstract::The link between co-morbid insomnia and depression has been demonstrated in numerous groups. Insomnia has been associated with: (1) an increased risk of developing subsequent depression; (2) an increased duration of established depression; and (3) relapse following treatment for depression. In addition, specific insom...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/11531130-000000000-00000

    authors: Riemann D,Workshop Participants.

    更新日期:2009-01-01 00:00:00

  • Therapeutic experience with temocillin in peritonitis.

    abstract::The therapeutic efficacy of the new beta-lactam antibiotic, temocillin, was studied in 30 critically ill patients with peritonitis, abscesses, bronchopneumonia, and serious soft tissue infections. Patients were treated with temocillin Ig intravenously twice daily. The isolated pathogens comprised mainly Escherichia co...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.2165/00003495-198500295-00042

    authors: Pfeiffer M,Fock RR

    更新日期:1985-01-01 00:00:00

  • Pharmacokinetics of various preparations of organic nitrates.

    abstract::The pharmacokinetics of different formulations of glyceryl trinitrate, isosorbide dinitrate, isosorbide 5-mononitrate and isosorbide 2-mononitrate are reviewed. ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-198700334-00004

    authors: Kampmann JP

    更新日期:1987-01-01 00:00:00

  • The Role of mTOR Inhibitors in the Treatment of Patients with Tuberous Sclerosis Complex: Evidence-based and Expert Opinions.

    abstract::Tuberous sclerosis complex (TSC) is a genetic disorder arising from mutations in the TSC1 or TSC2 genes. The resulting over-activation of the mammalian target of rapamycin (mTOR) signalling pathway leaves patients with TSC susceptible to the growth of non-malignant tumours in multiple organs. Previously, surgery was t...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-016-0552-9

    authors: Curatolo P,Bjørnvold M,Dill PE,Ferreira JC,Feucht M,Hertzberg C,Jansen A,Jóźwiak S,Kingswood JC,Kotulska K,Macaya A,Moavero R,Nabbout R,Zonnenberg BA

    更新日期:2016-04-01 00:00:00

  • Antiendotoxin strategies for the prevention and treatment of septic shock. New approaches and future directions.

    abstract::Therapy for Gram-negative sepsis remains unsatisfactory despite a concerted effort to develop new treatments for this common, life-threatening syndrome. Current research continues on several fronts to improve the treatment options available to clinicians in the management of these critically ill patients. Recently, a ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199855040-00002

    authors: Opal SM,Yu RL Jr

    更新日期:1998-04-01 00:00:00

  • Caspofungin: a review of its use in oesophageal candidiasis, invasive candidiasis and invasive aspergillosis.

    abstract::Echinocandins are a new class of antifungal agents with a novel mechanism of action (interference with fungal cell wall synthesis). Caspofungin (Cancidas), Caspofungin MSD) is the first echinocandin to be approved and is administered intravenously. Caspofungin 50 mg/day had similar efficacy to intravenous fluconazole ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200363200-00008

    authors: Keating G,Figgitt D

    更新日期:2003-01-01 00:00:00

  • Torasemide. A review of its pharmacological properties and therapeutic potential.

    abstract::Torasemide (torsemide) is a high-ceiling loop diuretic which acts on the thick ascending limb of the loop of Henle to promote rapid and marked excretion of water, sodium and chloride. Like furosemide (frusemide), its major site of action is from the luminal side of the cell. Torasemide is at least twice as potent as f...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199141010-00008

    authors: Friedel HA,Buckley MM

    更新日期:1991-01-01 00:00:00

  • Remifentanil: a review of its use during the induction and maintenance of general anaesthesia.

    abstract::Remifentanil (Ultiva), a fentanyl derivative, is an ultra-short acting, nonspecific esterase-metabolised, selective mu-opioid receptor agonist, with a pharmacodynamic profile typical of opioid analgesic agents. Notably, the esterase linkage in remifentanil results in a unique and favourable pharmacokinetic profile for...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200565130-00007

    authors: Scott LJ,Perry CM

    更新日期:2005-01-01 00:00:00

  • Optimal therapeutic strategies for resectable oesophageal or oesophagogastric junction cancer.

    abstract::Oesophageal cancer is the eighth most common cancer diagnosed worldwide, with almost half a million new cases diagnosed each year. Despite improvements in surgical and radiotherapy techniques and refinements of chemotherapeutic regimens, long-term survival, even from localized oesophageal cancer, remains poor. Surgica...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/11585460-000000000-00000

    authors: Bystricky B,Okines AF,Cunningham D

    更新日期:2011-03-26 00:00:00

  • Correction to: Isatuximab: First Approval.

    abstract::In the table 'Key clinical trials of isatuximab (Sanofi)', in the left-hand column. ...

    journal_title:Drugs

    pub_type: 杂志文章,已发布勘误

    doi:10.1007/s40265-020-01325-9

    authors: Dhillon S

    更新日期:2020-06-01 00:00:00

  • Cilazapril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in cardiovascular disease.

    abstract::Cilazapril is an orally active angiotensin converting enzyme (ACE) inhibitor which lowers peripheral vascular resistance without affecting heart rate. Like enalapril and ramipril it is a prodrug, and is hydrolysed after absorption to cilazaprilat, which has a long terminal phase elimination half-life permitting once d...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199141050-00008

    authors: Deget F,Brogden RN

    更新日期:1991-05-01 00:00:00

  • Fidaxomicin: a review of its use in patients with Clostridium difficile infection.

    abstract::Oral fidaxomicin (Dificid(®); Dificlir(®)) is a first-in-class macrocyclic antibacterial that is approved in several countries for the treatment of adult patients with Clostridium difficile-associated diarrhoea. Fidaxomicin 200 mg twice daily for 10 days was an effective and generally well tolerated treatment in adult...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-013-0134-z

    authors: Scott LJ

    更新日期:2013-10-01 00:00:00